None of the patients had clinical seizures the day before the PET scans

None of the patients had clinical seizures the day before the PET scans. To compare the brain area of metabolic change, the brain images were normalised with the Statistical Parametric Mapping software package (SPM2) with a 12 mm full width at half maximum (FWHM). one patient showed mild hypermetabolism in the right basal ganglia that correlated with mild rigidity and tonic posturing in the left extremities. Extent of cerebral metabolic changes correlates with the severity of catatonia accompanied by behavioural, motor, autonomic, and breathing abnormalities in anti-NMDAR encephalitis. Keywords: NMDA, Encephalitis, PET, Catatonia, Metabolism, Autoimmune encephalitis == Introduction == Anti-N-Methyl-D-aspartate receptor (NMDAR) encephalitis is a recently described form of autoimmune encephalitis that has characteristic clinical features that include psychosis, dyskinesia, encephalopathy, seizures, and autonomic dysfunctions. 13As N-type calcium channel blocker-1 one of the main symptom in anti-NMDAR encephalitis, catatonia presents with motor and behaviour abnormalities that include alterations in thought, mood, and vigilance. The common signs of catatonia are posturing, rigidity, mutism, and negativism. 4Half of anti-NMDAR encephalitis patients do not Rabbit polyclonal to PHYH display any abnormalities in brain magnetic resonance image (MRI) exams and the other half only show nonspecific changes in grey and white matter. 5 There are only a few studies that assess anti-NMDAR encephalitis with18F-Fluorodeoxyglucose positron-emission tomography (FDG-PET) scans. These studies found reduced glucose metabolism in temporal cortex regions6and global hypometabolism with a prominent focal intense hypermetabolic lesion in the right cerebellar cortex. 3In addition, a recent FDG-PET study reported an increased cerebral metabolism gradient along the frontotemporal to occipital axis that correlates with disease severity as assessed by a modified Rankin Scale. 7However, no studies have correlated metabolic changes in PET with detailed clinical symptoms such as the severity of catatonia and rigidity. Recently we experienced three serologically confirmed anti-NMDAR encephalitis with FDG-PET scan who presented with variable degrees of catatonia symptoms such as behavioural, motor, autonomic, and breathing abnormalities. We hereby report clinical course and PET findings with anti-NMDAR encephalitis == Case == == Summary of clinical history == Three patients were admitted to the Asan Medical Centre in Seoul, Korea between 2011 and 2012. Clinical findings in all three patients were summarized inTable 1 . These patients initially presented with marked agitation, psychotic behaviour, dyskinesis, and intermittent seizures. Seizures were observed in two patients (Patients 2 and 3) and disappeared 23 weeks after symptom onset. After admission, these patients showed varied degrees of catatonia symptoms such as behavioural, motor, autonomic, and breathing abnormalities. The patients were diagnosed with anti-NMDAR encephalitis after antibodies to NMDARs were found in their serum and cerebrospinal fluid (CSF). == Table 1 N-type calcium channel blocker-1 . == Summary of the clinical characteristics of all three patients F, frontal; Lt, left; PET, positron-emission tomography; U/E, upper extremities; Rt, right; MRI, magnetic resonance image; CSF, cerebrospinal fluid; WBC, white blood cell; NMDA, N-methyl-D-aspartate; Ab, antibody. During this acute phase of the encephalitis, all three patients had catatonia with rigidity and tonic posturing in their extremities that was more severe on the left side. The catatonic symptoms were relatively mild in Patient 1, were moderate in Patient 2, and were severe in Patient 3 (Table 1). Clinical improvements were obtained after methyl-prednisolone therapy in Patient 1, after methyl-prednisolone with electroconvulsive therapy (ECT) in Patient 2, and after methyl-prednisolone, immunoglobulin, and ECT in Patient 3. FDG-PET image were acquired 67 weeks after the onset of clinical symptoms (acute phase) N-type calcium channel blocker-1 and follow-up PET studies were performed at 1123 weeks from the onset of symptoms (recovery phase; Patient 1 at 11 weeks, Patient 2 at 23 weeks, and Patient 3 at 21 weeks). None of the patients had clinical seizures the day before the PET scans. To compare the brain area of metabolic change, the brain images were normalised with the Statistical Parametric Mapping software package (SPM2) with a 12 mm full width at half maximum (FWHM). For single-subject analyses, the scaled FDG-PET brain image of a patient was compared voxel-by-voxel with corresponding images from the age-matched normal control groups. One-sided, two sample t-tests for detecting.